An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis

• Auteurs principaux: Lluís Puig (Auteur), Mark Lomaga (Auteur), Kristin Hollister (Auteur), Yves Dutronc (Auteur), Lovisa Berggren (Auteur), Peter C.M. van de Kerkhof (Auteur)
• Format: Livre
• Publié: Medical Journals Sweden, 2020-12-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806)....